<$BlogRSDURL$>
Return to Main Page | Ragout: We Need Me-Too Drugs Too
Ragout
A Spicy Stew of Economics, Politics, Data, Food, Carpentry, etc.
 
Tuesday, July 20, 2004

We Need Me-Too Drugs Too


In a recent article in the NY Review of Books, Marcia Angell, former editor of The New England Journal of Medicine, promises to tell us "The Truth about the Drug Companies." Her version of the truth turns out to be pretty much the same rant put out by Ralph Nader's health policy organizations. Indeed, her 19 footnotes are mainly citations to Nader organizations, other advocacy organizations, newspapers, magazines, and also a blog, and rarely to academic research.

Angell makes one particularly wrong-headed proposal:
We need to get the industry to focus on discovering truly innovative drugs instead of turning out me-too drugs...The me-too business is made possible by the fact that the FDA usually approves a drug only if it is better than a placebo...

The me-too market would collapse virtually overnight if the FDA made approval of new drugs contingent on their being better in some important way than older drugs already on the market. Probably very few new drugs could meet that test. By default, then, drug companies would have to concentrate on finding truly innovative drugs.
There are at least two problems with this plan. First, there's no reason to think that banning me-too drugs would spur more research into innovative drugs. There isn't some fixed pot of industry research money. The drug industry, and its investors, are presumably already doing all the research into breakthrough drugs that they think will be profitable. If they can't put their money into me-too drugs, they're just as likely to invest in Las Vegas casinos, Hollywood movies, or maybe munitions, as in truly innovative pharmaceutical research.

Second, banning me-too drugs would raise drug prices. Me-too drugs, by definition, are close substitutes for drugs already on the market. Hence, they increase competition and lower drug prices. It may not be the optimal way to set drug prices, at least if the me-too drugs are really identical to the old ones, but it could well be a second-best solution.

Another way that Angell's proposal would raise drug prices is to increase the cost of clinical trials, which account for most of the cost of developing a new drug. Consider a drug trial where 50% of those given a pill recover, while only 25% of those given a placebo do. Now consider a me-too drug that worked for 55%. Angell wants us to test this drug against the old 50% pill, rather than a placebo. But to do this we need a dramatically larger study. In fact, about 25 time larger: 2500 patients instead of 100! These kind of costs could easily rule out any possibility of doing the research. And that would mean that the extra 5% won't ever get to benefit from the drug. Further, if the "me-too" drug doesn't benefit exactly the same types of people, the number of potential beneficiaries is higher than 5%.

I've always been puzzled: why do public interest organizations spend so much time criticizing the drug industry for "wasteful" research and marketing, and so little time criticizing the billions spent on the development and marketing of marketing of movies, casinos, candy, and all the other products that are a lot less valuable than new pharmaceuticals?

 
|










































Number 1 in Ragout Economics!

ARCHIVES
March 2004 / April 2004 / May 2004 / June 2004 / July 2004 / August 2004 / September 2004 / October 2004 / November 2004 / December 2004 / January 2005 / April 2005 / May 2005 / June 2005 / July 2005 / August 2005 / September 2005 / October 2005 /

LINKS
First Team
Angry Bear
Atrios
Crooked Timber
Brad DeLong
Econbrowser
Economist's View
Freakonomics
Mark Kleiman
Nathan Newman
Political Animal
Max Sawicky
Brian Setser
Sock Thief
Talking Points Memo
Tapped
Matthew Yglesias

Second Opinion
Stephen Bainbridge
Marginal Revolution
Andrew Samwick
The Volokh Conspiracy

Third Way
Fafblog
NewDonkey

Fourth Estate
Economic Reporting Review
New York Times
Slate
Washington Post

Fifth Republic
Ceteris-Paribus
Econoclaste
Le Figaro
Le Monde

Sixth Sense
Deltoid
The Intersection
In the Pipeline
What's New

Politics & Polls
Daily Kos
Donkey Rising
Electoral Vote Predictor
MyDD
PollingReport
PollKatz
Rasmussen Tracking Polls

Other
Art Sucks
Enzo Titolo
L’esprit d’escalier
A Level Gaze
Approximately Perfect


EMAIL
ragoutchef at yahoo dot com

[ATOM]

Powered by Blogger